AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06069739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical activity
Description: Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline.
Study NCT02257528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02303639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
Study NCT02303639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug therapy
Description: Amiodarone (or sotalol) for prevention of VT/VF relapses
Study NCT03159832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3824
Description: All subjects were given SHR3824 20mg only one time.
Study NCT04524689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Study NCT00844402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral, 10 mg, daily, 48 weeks
Study NCT04524689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study NCT04524689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
Study NCT04524689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study NCT01416077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid optimisation
Description: Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.~4. If despite CI > 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65.
Study NCT01406314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: Intravenous infusion for approximately 48hours followed by subcutaneous injection
Study NCT04524689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02258659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablets administered once daily according to dosing recommendations per product monograph
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Tablets administered orally once daily with food
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR
Description: Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered orally once daily
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Solution administered orally
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Unboosted Drug
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given PO
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat TOS
Description: Tablets for oral suspension
Study NCT02016924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension
Study NCT02258659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT02258659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02258659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03078569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: treatment with testosterone gel
Study NCT03064945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livia
Description: Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
Study NCT03064945 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Livia
Description: Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
Study NCT00158197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management voucher
Description: participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
Study NCT03861091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
Study NCT03861091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Dose not applicable, given once 7-21 days prior to initiation of SBRT
Study NCT02472158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chlorhexidine-gel-impregnated dressing
Description: Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
Study NCT00863759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of intraocular lens (IOL)
Description: implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye.
Study NCT01791998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance thermal imaging
Description: Undergo MR-thermal image guided LITT
Study NCT01791998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser interstitial thermal therapy
Description: Undergo MR-thermal image guided LITT
Study NCT04204382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin Injection
Description: Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
Study NCT04204382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Injection
Description: Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
Study NCT04204382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Kushen Injection（CKI）
Description: CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
Study NCT01913457 — intervention group
Intervention type: RADIATION
Intervention: Ultrasound Doppler
Description: Doppler Ultrasound recording on external right chest wall
Study NCT00214253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Description: Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection
Study NCT02472158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane film dressing
Description: Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
Study NCT01664702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Products
Description: See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
Study NCT01664702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Servings
Description: Continue baseline consumption of one or fewer servings of dairy per day
Study NCT01449292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment plus Optimal Medical Therapy
Description: Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study NCT01449292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study NCT00670722 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Intervention at the discretion of the physician
Study NCT00670722 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Intervention at the discretion of the physician
Study NCT00670722 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Intervention at the discretion of the physician
Study NCT02144038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: pan-PIM inhibitor
Study NCT02797522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
Study NCT02144038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: PI3K-alpha inhibitor
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Participants take entecavir OR tenofovir daily throughout the study.
Study NCT02797522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: Participants take entecavir OR tenofovir daily throughout the study.
Study NCT06541769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb hypothermia
Description: Limb hypothermia with special gel-gloves
Study NCT06541769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb compression
Description: compression with sterile one way Latex gloves. Size measured for every Patient individually
Study NCT01251770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% NaCl/dextrose 5%
Description: Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
Study NCT01251770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% NaCl/dextrose 5%
Description: Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
Study NCT02056626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Study NCT00234702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
Study NCT00234702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02188680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAPS diet
Description: FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
Study NCT02188680 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low FODMAPS diet
Description: FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
Study NCT00725335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection without Pringle
Description: Radical excision of liver cancer without the procedure of pringle manoeuvre
Study NCT00725335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative resection with Pringle manoeuvre
Description: curative resection liver cancer under pringle manoeuvre
Study NCT02015507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivacaftor
Study NCT02015507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor
Study NCT02015507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Study NCT02015507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin
Study NCT02015507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Study NCT02511444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GBS culture and real time PCR
Description: patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
Study NCT03059277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Description: Intravitreal Aflibercept 2mg
Study NCT02493452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Study NCT02493452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04200638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Description: The canal fluid sample before and after will evaluate after root canal instrumentation
Study NCT00843505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Smoking Cessation Program
Description: Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
Study NCT00843505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Quitline Smoking Cessation Program
Description: Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
Study NCT02308397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal gluten containing bread
Description: Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
Study NCT02308397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced gliadins content
Description: Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
Study NCT02308397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced ATIs content
Description: Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
Study NCT02308397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced overall protein content
Description: Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
Study NCT01598077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Study NCT04884919 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Regular Gauze
Description: Regular gauze
Study NCT04884919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Dressing
Description: Dressing made of chitosan material
Study NCT04611165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~* EBRT begins 2-7 days after the first dose of nivolumab.~* The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies.
Study NCT01016262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-002
Description: MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
Study NCT01016262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
Study NCT01016262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canasa®
Description: Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
Study NCT01914770 — intervention group
Intervention type: DRUG
Intervention: Belimumab 1 mg/kg
Description: Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).